{"id":10305,"date":"2023-11-10T16:45:16","date_gmt":"2023-11-10T15:45:16","guid":{"rendered":"http:\/\/cilcare.com\/?page_id=10305"},"modified":"2025-02-24T13:52:24","modified_gmt":"2025-02-24T12:52:24","slug":"in-vivo-studies","status":"publish","type":"page","link":"https:\/\/www.cilcare.com\/jp\/our-missions-external-innovation\/in-vivo-studies\/","title":{"rendered":"\u8074\u899a\u8010\u6027 &amp; \u5b89\u5168\u6027\u8a66\u9a13"},"content":{"rendered":"<div data-elementor-type=\"wp-page\" data-elementor-id=\"10305\" class=\"elementor elementor-10305\" data-elementor-settings=\"{&quot;ha_cmc_init_switcher&quot;:&quot;no&quot;}\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1297866 e-flex e-con-boxed e-con e-parent\" data-id=\"1297866\" data-element_type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;,&quot;_ha_eqh_enable&quot;:false}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a631965 elementor-widget elementor-widget-heading\" data-id=\"a631965\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">\u8074\u899a\u8010\u6027 &amp; \u5b89\u5168\u6027\u8a66\u9a13<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-aa13f3f e-flex e-con-boxed e-con e-parent\" data-id=\"aa13f3f\" data-element_type=\"container\" data-settings=\"{&quot;_ha_eqh_enable&quot;:false}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5063b1e elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"5063b1e\" data-element_type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"translation-block\">\u591a\u304f\u306e\u6cbb\u7642\u85ac\uff08\u8074\u899a\u3084\u8033\u75be\u60a3\u3068\u306f\u7121\u95a2\u4fc2\u306e\u9069\u5fdc\u75c7\u3092\u5bfe\u8c61\u3068\u3057\u305f\u3082\u306e\u3092\u542b\u3080\uff09\u306b\u3064\u3044\u3066\u3001\u8074\u899a\u306e\u5b89\u5168\u6027\u3092\u691c\u8a3c\u3059\u3079\u304d\u3067\u3042\u308b\u3053\u3068\u304c\u81e8\u5e8a\u30c7\u30fc\u30bf\u306b\u3088\u308a\u78ba\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u8074\u5668\u6bd2\u6027\u304a\u3088\u3073\u95a2\u9023\u3059\u308b\u8074\u899a\u75c5\u5909\u306f\u3001\u85ac\u3092\u670d\u7528\u3057\u3066\u3044\u308b\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306b\u5f71\u97ff\u3092\u53ca\u307c\u3057\u3001\u751f\u6d3b\u306e\u8cea\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/p><p class=\"translation-block\">\u3055\u3089\u306b\u3001\u73fe\u5728\u3001\u96e3\u8074\u307e\u305f\u306f\u8033\u9cf4\u308a\u306b\u82e6\u3057\u30805\u5104\u4eba\u4ee5\u4e0a\u306e\u4eba\u3005\u306e\u751f\u6d3b\u3092\u6539\u5584\u3059\u308b\u305f\u3081\u306e\u6709\u671b\u306a\u6cbb\u7642\u6cd5\u3084\u533b\u7642\u6a5f\u5668\u304c\u6570\u591a\u304f\u958b\u767a\u4e2d\u3067\u3059\u3002\u3053\u308c\u3089\u306e\u8074\u899a\u95a2\u9023\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u5b89\u5168\u6027\u306f\u3001\u898f\u5236\u5f53\u5c40\u306b\u3088\u3063\u3066\u627f\u8a8d\u3055\u308c\u308b\u524d\u306b\u5fc5\u305a\u691c\u8a3c\u3055\u308c\u308b\u5fc5\u8981\u304c\u3042\u308a\u307e\u3059\u3002<\/p><p class=\"translation-block\">\u30b7\u30eb\u30b1\u30a2\u306f\u3001\u65e9\u671f\u958b\u767a\u6bb5\u968e\u3068\u5f8c\u671f\u5b89\u5168\u6027\u8a55\u4fa1\u3092\u30b5\u30dd\u30fc\u30c8\u3059\u308b\u6bd4\u985e\u306e\u306a\u3044\u8074\u5668\u6bd2\u6027\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3057\u307e\u3059\u3002\u3052\u3063\u6b6f\u985e\u304a\u3088\u3073\u5927\u578b\u52d5\u7269\u306b\u304a\u3044\u3066\u3001\u6a5f\u80fd\u7684\u3001\u884c\u52d5\u7684\u3001\u304a\u3088\u3073\u5f62\u614b\u5b66\u7684\u8a55\u4fa1\u9805\u76ee\u3092\u7528\u3044\u3066\u524d\u81e8\u5e8a\u8a66\u9a13\u3092\u5b9f\u65bd\u3057\u307e\u3059\u3002\u88fd\u5264\u306e\u5b89\u5168\u6027\u3001\u85ac\u5264\u5019\u88dc\u81ea\u4f53\u306e\u5f71\u97ff\u8a55\u4fa1\u3001\u8074\u5668\u6bd2\u6027\u53c2\u7167\u5316\u5408\u7269\u3068\u306e\u6bd4\u8f03\u8a55\u4fa1\u3092\u3059\u308b\u5834\u5408\u3067\u3082\u3001\u30b7\u30eb\u30b1\u30a2\u306f\u3001\u5185\u8033\u306b\u5b89\u5168\u306a\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3059\u308b\u305f\u3081\u306b\u5fc5\u8981\u306a\u3082\u306e\u3092\u7684\u78ba\u306b\u63d0\u4f9b\u3059\u308b\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002<\/p><p>\u8a66\u9a13\u8a55\u4fa1\u306b\u306f\u4ee5\u4e0b\u304c\u542b\u307e\u308c\u307e\u3059\uff1a<\/p><ul><li>\u5185\u6709\u6bdb\u7d30\u80de\u3068\u8074\u795e\u7d4c\uff08ABR\uff09\u304a\u3088\u3073\u5916\u6709\u6bdb\u7d30\u80de\uff08DPOAE\uff09\u306e\u6d3b\u52d5\u6027\u3068\u5b8c\u5168\u6027\u3092\u8a55\u4fa1\u3059\u308b\u305f\u3081\u306eABR\u304a\u3088\u3073DPOAE<\/li><li>\u30b7\u30ca\u30d7\u30b9\u6a5f\u80fd\u3092\u7814\u7a76\u3059\u308b\u305f\u3081\u306e\u6ce2\u5f62I\u89e3\u6790<\/li><li>\u8033\u9cf4\u308a\u306e\u5b58\u5728\u3092\u8a55\u4fa1\u3059\u308b\u305f\u3081\u306eGPIAS\uff08\u30ae\u30e3\u30c3\u30d7\u524d\u6291\u5236\u8074\u899a\u30b9\u30bf\u30fc\u30c8\u30eb\uff09<\/li><li>\u8778\u725b\u306e\u640d\u50b7\u3092\u8a55\u4fa1\u3059\u308b\u305f\u3081\u306e\u6709\u6bdb\u7d30\u80de\u3068\u30ea\u30dc\u30f3\u30b7\u30ca\u30d7\u30b9\u306e\u6570\u3092\u8a08\u6e2c\u3059\u308b\u7d44\u7e54\u75c5\u7406\u5b66<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-c326e40 e-flex e-con-boxed e-con e-parent\" data-id=\"c326e40\" data-element_type=\"container\" id=\"glp\" data-settings=\"{&quot;_ha_eqh_enable&quot;:false}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c74290a elementor-widget elementor-widget-heading\" data-id=\"c74290a\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">GLP\u8074\u5668\u6bd2\u6027\u8a66\u9a13\/GLP\u6bd2\u6027\u5b66\u304a\u3088\u3073\u6bd2\u6027\u52d5\u614b\u5b66<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-31ad326 elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"31ad326\" data-element_type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"translation-block\">\u30b7\u30eb\u30b1\u30a2\u306f2017\u5e74\u306b\u3001\u30dc\u30b9\u30c8\u30f3\u3092\u62e0\u70b9\u3068\u3059\u308b<a href=\"https:\/\/cbset.com\/\" target=\"_self\"><strong>GLP\u6e96\u62e0\u306e\u751f\u7269\u533b\u5b66\u7814\u7a76\u6a5f\u95a2\u3067\u3042\u308bCBSET, Inc.<\/strong><\/a>\u3068\u6226\u7565\u7684\u63d0\u643a\u3092\u7d50\u3073\u307e\u3057\u305f\u3002\u3053\u306e\u63d0\u643a\u306f\u3001\u898f\u5236\u57fa\u6e96\u306b\u6cbf\u3063\u305fGLP\u74b0\u5883\u4e0b\u3067\u3001\u8074\u899a\u6a5f\u80fd\u3092\u8a55\u4fa1\u3059\u308b\u305f\u3081\u306e\u6700\u5148\u7aef\u306e\u524d\u81e8\u5e8a\u30b5\u30fc\u30d3\u30b9\u3092\u6cbb\u7642\u85ac\u304a\u3088\u3073\u533b\u7642\u6a5f\u5668\u958b\u767a\u8005\u306b\u63d0\u4f9b\u3059\u308b\u3053\u3068\u3067\u3059\u3002<\/p><p class=\"translation-block\">\u3053\u306e\u9023\u643a\u306b\u3088\u308a\u3001\u8074\u899a\u8a55\u4fa1\u306b\u304a\u3051\u308b\u79d1\u5b66\u7684\u5c02\u9580\u77e5\u8b58\u3068\u3001GLP\u6e96\u62e0\u306e\u524d\u81e8\u5e8a\u8a66\u9a13\u306e\u8c4a\u5bcc\u306a\u5b9f\u7e3e\u304c\u878d\u5408\u3057\u3001\u898f\u5236\u5f53\u5c40\u3078\u306e\u7533\u8acb\u306b\u304a\u3051\u308b\u30ea\u30b9\u30af\u3092\u8efd\u6e1b\u3059\u308b\u5f37\u529b\u306a\u6226\u7565\u304c\u69cb\u7bc9\u3055\u308c\u307e\u3059\u3002\u4e00\u822c\u6bd2\u6027\u8a66\u9a13\u304b\u3089\u5916\u79d1\u7684\u30b5\u30fc\u30d3\u30b9\u307e\u3067\u3001\u5f53\u793e\u306e\u30c1\u30fc\u30e0\u306f\u3001\u304a\u5ba2\u69d8\u306eIND\u30a2\u30d7\u30ed\u30fc\u30c1\u3068\u30d7\u30ed\u30b8\u30a7\u30af\u30c8\u306e\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u306b\u6cbf\u3063\u305f\u524d\u81e8\u5e8a\u30d7\u30ed\u30b0\u30e9\u30e0\u3092\u30ab\u30b9\u30bf\u30de\u30a4\u30ba\u306b\u5bfe\u5fdc\u3057\u3001\u518d\u73fe\u6027\u306e\u3042\u308b\u5f37\u56fa\u306a\u30c7\u30fc\u30bf\u306e\u53d6\u5f97\u3092\u5b9f\u73fe\u3057\u307e\u3059\u3002<\/p><p class=\"translation-block\"><strong><a href=\"https:\/\/cbset.com\/\" target=\"_self\">CBSET\u2019<\/a>s<\/strong>  \u306e\u6700\u5148\u7aef\u7814\u7a76\u65bd\u8a2d\u306e\u7279\u5fb4<\/p><ul><li>GLP\u6e96\u62e0\u306e\u7814\u7a76\u30b5\u30fc\u30d3\u30b9\u306e\u8c4a\u5bcc\u306a\u7d4c\u9a13<\/li><li>AAALAC\u8a8d\u5b9a\u3001OLAW\u4fdd\u8a3c\u306e\u52d5\u7269\u7814\u7a76\u65bd\u8a2d<\/li><li>\u81e8\u5e8a\u7363\u533b\u5e2b\u304a\u3088\u3073\u7363\u533b\u75c5\u7406\u5b66\u8005\uff08\u3044\u305a\u308c\u3082\u8a8d\u5b9a\u533b\uff09\u306b\u3088\u308b\u4f53\u5236<\/li><li>FDA\uff08\u7c73\u98df\u54c1\u533b\u85ac\u54c1\u5c40\uff09\u67fb\u5bdf\u306b\u304a\u3051\u308b\u826f\u597d\u306a\u5b9f\u7e3e<\/li><li>\u3052\u3063\u6b6f\u985e\u304a\u3088\u3073\u5927\u578b\u52d5\u7269\u306e\u98fc\u80b2\u65bd\u8a2d<\/li><\/ul><h3><strong>\u8074\u899a\u306e\u5b89\u5168\u6027\u3092\u3069\u306e\u3088\u3046\u306b\u8a55\u4fa1\u3059\u3079\u304d\u304b\uff1f<\/strong><\/h3><p>FDA\u306e\u30ac\u30a4\u30c0\u30f3\u30b9\u6587\u66f8\u3067\u306f\u30012\u3064\u306e\u65b9\u6cd5\u8ad6\u3092\u7528\u3044\u305f\u8074\u899a\u306e\u5b89\u5168\u6027\u8a55\u4fa1\u3092\u6307\u5b9a\u3057\u3066\u3044\u307e\u3059*\uff1a<\/p><p class=\"translation-block\"><strong>1\/ In vivo\u8a55\u4fa1\uff1a\u8074\u6027\u8133\u5e79\u53cd\u5fdc\uff08ABR\uff09\u306e\u6e2c\u5b9a<\/strong><\/p><p>\u8074\u6027\u8133\u5e79\u53cd\u5fdc\uff08ABR\uff09\u306f\u3001\u982d\u76ae\u4e0a\u306b\u88c5\u7740\u3057\u305f\u96fb\u6975\u3067\u8a18\u9332\u3055\u308c\u308b\u96fb\u4f4d\u3067\u3059\u3002\u3053\u306e\u975e\u4fb5\u8972\u7684\u306a\u65b9\u6cd5\u306b\u3088\u308a\u3001\u8074\u899a\u5fdc\u7b54\u306e\u95be\u5024\u3092\u6e2c\u5b9a\u3059\u308b\u3053\u3068\u304c\u53ef\u80fd\u3067\u3059\u3002ABR\u306f\u3052\u3063\u6b6f\u985e\u3068\u30d2\u30c8\u306e\u9593\u3067\u30c8\u30e9\u30f3\u30b9\u30ec\u30fc\u30b7\u30e7\u30ca\u30eb\u306a\u8a55\u4fa1\u304c\u53ef\u80fd\u3067\u3042\u308a\u3001\u65b0\u751f\u5150\u306e\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u306b\u4e00\u822c\u7684\u306b\u4f7f\u7528\u3055\u308c\u307e\u3059\u3002<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7a03e0c elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"7a03e0c\" data-element_type=\"widget\" id=\"vectors\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>2\/ Ex vivo\u8a55\u4fa1\uff1a\u7d30\u80de\u8778\u725b\u56f3<\/strong><\/p><p class=\"translation-block\">\u7d30\u80de\u8778\u725b\u56f3\u306b\u3088\u308a\u3001\u8778\u725b\u306e\u5185\u6709\u6bdb\u7d30\u80de\u304a\u3088\u3073\u5916\u6709\u6bdb\u7d30\u80de\u306b\u304a\u3051\u308b\u8074\u5668\u6bd2\u6027\u306b\u3088\u308b\u640d\u50b7\u3092\u7d44\u7e54\u5b66\u7684\u306b\u8a55\u4fa1\u3059\u308b\u624b\u6cd5\u3067\u3001\u6a5f\u80fd\u969c\u5bb3\u306e\u4e88\u6e2c\u3055\u308c\u308b\u30d1\u30bf\u30fc\u30f3\u306b\u5bfe\u5fdc\u3057\u305f\u89e3\u5256\u5b66\u7684\u306a\u5c40\u5728\u3092\u7279\u5b9a\u3059\u308b\u3053\u3068\u304c\u3067\u304d\u307e\u3059<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>auditory tolerance &amp; safety studies Clinical data confirms that many therapeutic compounds, including those targeting indications unrelated to hearing and otic disorders, should be tested for auditory safety. Ototoxicity and associated auditory pathologies may affect millions of patients taking medication, potentially contributing to a diminished quality of life. Additionally, several promising therapeutics and devices are currently in development for improving the lives of more than 500 million people suffering from hearing loss or tinnitus. The auditory safety of these solutions must be tested before being approved by regulatory authorities. CILcare provides unparalleled ototoxicity services that support early-stage development and late-stage safety assessments. We conduct preclinical trials in rodents and larger [&hellip;]<\/p>","protected":false},"author":6,"featured_media":0,"parent":9055,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-10305","page","type-page","status-publish","hentry","entry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>auditory tolerance &amp; safety studies - Cilcare<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cilcare.com\/jp\/our-missions-external-innovation\/in-vivo-studies\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"auditory tolerance &amp; safety studies - Cilcare\" \/>\n<meta property=\"og:description\" content=\"auditory tolerance &amp; safety studies Clinical data confirms that many therapeutic compounds, including those targeting indications unrelated to hearing and otic disorders, should be tested for auditory safety. Ototoxicity and associated auditory pathologies may affect millions of patients taking medication, potentially contributing to a diminished quality of life. Additionally, several promising therapeutics and devices are currently in development for improving the lives of more than 500 million people suffering from hearing loss or tinnitus. The auditory safety of these solutions must be tested before being approved by regulatory authorities. CILcare provides unparalleled ototoxicity services that support early-stage development and late-stage safety assessments. We conduct preclinical trials in rodents and larger [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cilcare.com\/jp\/our-missions-external-innovation\/in-vivo-studies\/\" \/>\n<meta property=\"og:site_name\" content=\"Cilcare\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-24T12:52:24+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data1\" content=\"2\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cilcare.com\/our-missions-external-innovation\/in-vivo-studies\/\",\"url\":\"https:\/\/www.cilcare.com\/our-missions-external-innovation\/in-vivo-studies\/\",\"name\":\"auditory tolerance &amp; safety studies - Cilcare\",\"isPartOf\":{\"@id\":\"https:\/\/www.cilcare.com\/#website\"},\"datePublished\":\"2023-11-10T15:45:16+00:00\",\"dateModified\":\"2025-02-24T12:52:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cilcare.com\/our-missions-external-innovation\/in-vivo-studies\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cilcare.com\/our-missions-external-innovation\/in-vivo-studies\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cilcare.com\/our-missions-external-innovation\/in-vivo-studies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cilcare.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Our missions &#8211; External innovation\",\"item\":\"https:\/\/www.cilcare.com\/our-missions-external-innovation\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"auditory tolerance &amp; safety studies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cilcare.com\/#website\",\"url\":\"https:\/\/www.cilcare.com\/\",\"name\":\"Cilcare\",\"description\":\"Making hearing a priority\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cilcare.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"auditory tolerance &amp; safety studies - Cilcare","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cilcare.com\/jp\/our-missions-external-innovation\/in-vivo-studies\/","og_locale":"ja_JP","og_type":"article","og_title":"auditory tolerance &amp; safety studies - Cilcare","og_description":"auditory tolerance &amp; safety studies Clinical data confirms that many therapeutic compounds, including those targeting indications unrelated to hearing and otic disorders, should be tested for auditory safety. Ototoxicity and associated auditory pathologies may affect millions of patients taking medication, potentially contributing to a diminished quality of life. Additionally, several promising therapeutics and devices are currently in development for improving the lives of more than 500 million people suffering from hearing loss or tinnitus. The auditory safety of these solutions must be tested before being approved by regulatory authorities. CILcare provides unparalleled ototoxicity services that support early-stage development and late-stage safety assessments. We conduct preclinical trials in rodents and larger [&hellip;]","og_url":"https:\/\/www.cilcare.com\/jp\/our-missions-external-innovation\/in-vivo-studies\/","og_site_name":"Cilcare","article_modified_time":"2025-02-24T12:52:24+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cilcare.com\/our-missions-external-innovation\/in-vivo-studies\/","url":"https:\/\/www.cilcare.com\/our-missions-external-innovation\/in-vivo-studies\/","name":"auditory tolerance &amp; safety studies - Cilcare","isPartOf":{"@id":"https:\/\/www.cilcare.com\/#website"},"datePublished":"2023-11-10T15:45:16+00:00","dateModified":"2025-02-24T12:52:24+00:00","breadcrumb":{"@id":"https:\/\/www.cilcare.com\/our-missions-external-innovation\/in-vivo-studies\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cilcare.com\/our-missions-external-innovation\/in-vivo-studies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.cilcare.com\/our-missions-external-innovation\/in-vivo-studies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cilcare.com\/"},{"@type":"ListItem","position":2,"name":"Our missions &#8211; External innovation","item":"https:\/\/www.cilcare.com\/our-missions-external-innovation\/"},{"@type":"ListItem","position":3,"name":"auditory tolerance &amp; safety studies"}]},{"@type":"WebSite","@id":"https:\/\/www.cilcare.com\/#website","url":"https:\/\/www.cilcare.com\/","name":"Cilcare","description":"Making hearing a priority","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cilcare.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"}]}},"_links":{"self":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/pages\/10305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/comments?post=10305"}],"version-history":[{"count":62,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/pages\/10305\/revisions"}],"predecessor-version":[{"id":13371,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/pages\/10305\/revisions\/13371"}],"up":[{"embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/pages\/9055"}],"wp:attachment":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/media?parent=10305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}